KR100535228B1 - 란소프라졸함유 경질캅셀제의 제조방법 - Google Patents
란소프라졸함유 경질캅셀제의 제조방법 Download PDFInfo
- Publication number
- KR100535228B1 KR100535228B1 KR10-2003-0015149A KR20030015149A KR100535228B1 KR 100535228 B1 KR100535228 B1 KR 100535228B1 KR 20030015149 A KR20030015149 A KR 20030015149A KR 100535228 B1 KR100535228 B1 KR 100535228B1
- Authority
- KR
- South Korea
- Prior art keywords
- lansoprazole
- oil
- producing
- acid
- calcium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
- 란소프라졸을 오일류 또는 지방산에 용해 또는 분산시키고, 유화제와 알카리화제가 함유된 친수성 고분자 화합물이 용해된 팽윤액에 가하고 교반한다음, 여기에 첨가제를 가하여 유제를 제조하고, 이 혼합용액을 염화칼슘 수용액에 분사하여 막을 형성한다음, 여과, 세척하여 칼슘이온을 제거하고 동결건조하여 100∼1500 ㎛의 크기의 펠렛을 제조하고, 필름코팅 및 장용코팅을 실시하여 얻어진 란소프라졸 함유 펠렛을 경질젤라틴 캅셀에 충진하여 제조함을 특징으로 하는 경질캅셀제의 제조방법.
- 제 1항에 있어서, 알칼리화제가 메칠글루카민인 란소프라졸함유 경질캅셀제의 제조방법.
- 제 1항에 있어서, 오일 또는 그 지방산을 이용한 란소프라졸의 조성비가 0.5∼5:1인 란소프라졸 함유 경질캅셀제의 제조방법
- 제 1항에 있어서, 오일이라 함은 스테아릴 글리실레티네이트(stearyl glycyrrhetinate), 토코페릴 아세테이트 (tocopheryl acetate), 판테놀 (panthenol), 포스파티딜콜린 (phosphatidylcholine)류; 글리세릴 스테아레이트 (glyceryl stearate), 카프틸릭/카프릭 트리글리세라이드 (captylic/capric triglyceride), 세틸 옥탄올레이트 (cetyl octanolate), 이소프로필 미리스테이트 (isopropyl myristate), 세테아틸 옥타노에이트 (ceteatyl octanoate), 부틸렌 글리콜 디카프틸레이트/디카프레이트(butylene glycol dicaptylate/dicaprate), 수소화 카스터 오일 (hydrogenated castor oil), 모노글리세라이드 (mono-glycerides), 디글리세라이드 (diglycerides), 트리글리세라이드 (triglycerides) 등의 에스테르류; 비스왁스 (beeswax), 카나우바 왁스 (carnauba wax), 올리브유 (olive oil), 호호바유 (jojoba oil), 혼성 해바라기유 (hybrid sunflower(Helian thus annuus) oil)의 식물류; 미네랄 오일, 스쿠알렌 (squalene), 스쿠알란(squalane), 모노글리세라이드, 디글리세라이드, 트리글리세라이드, 중간 사슬 글리세라이드, 미글리올(myglyol), 크레모포(cremophor), 수소화 캐스터 오일, 옥수수유, 대두유, 깨유, 면실유 또는 지용성 비타민 중에서 선택된 1종 또는 그 이상의 혼합액을 사용하는 란소프라졸함유 경질캅셀제의 제조방법.
- 제 1항에 있어서, 지방산이라 함은 리놀렌산 (linoleic acid), 스테아린산(stearic acid), 올레인산(oleic acid), 세틸 알콜(cetyl alcohol), 스테아릴 알콜 (stearyl alcohol), 미리스틱산(myristic acid), 미소프로필미리스틱산 또는 라우릭산 (lauric acid)중에서 1종 또는 그 이상 혼합하여 사용하는 란소프라졸함유 경질캅셀제의 제조방법.
- 제 1항에 있어서, 펠렛을 제조하는 방법이 분사 노즐을 사용하여 0.3∼2.5 mm의 직경을 가지는 란소프라졸 함유 경질캅셀제의 제조방법.
- 제 1항에 있어서, 펠렛을 형성하는 친수성 고분자 기제로 히드록시프로필메칠셀룰로오스(HPMC), 히드록시프로필셀루로오스(HPC), 카르복시메칠셀룰로오스(carboxymethylcellulose) 및 그 나트륨염, 칼슘염, 카라기난(carrageenan), 알긴산(alginic acid) 및 그 마그네슘염, 소디움염, 칼슘염, 포비돈(povidone), 폴리비닐알킬(polyvinyl alcohol), 트라가칸트고무(tragacanth gum), 키토산(chitosan), 키틴(chitin)중에서 선택된 1종 또는 그 이상 혼합하여 사용하는 란소프라졸함유 경질캅셀제의 제조방법.
- 제 1항에 있어서, 용해를 촉진하는 유화제로 소디움라우릴술페이트(Sodium lauryl sulfate), 히드록시프로필메칠셀룰로오스(HPMC), 히드록시프로필셀루로오스(HPC), 카르복시메칠셀룰로오스(carboxymethylcellulose) 및 그의 나트륨염, 칼슘염, 카라기난(carrageenan), 알긴산(alginic acid) 및 그의 마그네슘염, 소디움염, 칼슘염, 포비돈(povidone), 폴리비닐알콜(polyvinyl alcohol), 트라가칸트고무(tragacanth gum), 키토산(chitosan), 키틴(chitin), 트윈(Tween), 폴리옥실35피마자유(polyoxyl 35 castor oil), 폴리옥실40수소화피마자유(polyoxyl 40 hydrogenated castor oil), 폴리옥실10올레일에테르(polyoxyl 10 oleyl ether), 폴리옥실20세토스테아릴에테르(polyoxyl 20 cetostearyl ether), 폴리옥실40스테아린산(polyoxyl 40 stearate), 올레일알콜(Oleyl alcohol), 레시친(lecithin), 디에탄올아민(diethanolamine), 콜레스테롤(cholesterol), 폴록사머(poloxamer), 트롤아민(Trolamine), 왁스(wax)중에서 선택된 1종 또는 그 이상을 혼합하여 사용하는 란소프라졸함유 경질캅셀제의 제조방법.
- 제 1항에 있어서, 펠렛의 형태를 유지하기 위한 첨가제로는 전분(starch), 전호화 전분(pregelatinized starch) 유당(lactode), 만니톨(mannitol), 솔비톨(sorbitol), 설탕(sucrose), 덱스트린(dextrin), 카보머 910, 934, 934P, 940, 941, 1342, 칼슘카보네이트(calcium carbonate), 칼슘포스페이트디베이직(calcium phosphate dibasic), -트리베이직(tribasic), 칼슘설페이트(calcium sulfate) 또는 탈크 중에서 선택된 1종 또는 그 이상을 혼합하여 사용하는 란소프라졸 함유 경질캅셀제의 제조방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0015149A KR100535228B1 (ko) | 2003-03-11 | 2003-03-11 | 란소프라졸함유 경질캅셀제의 제조방법 |
AU2003224467A AU2003224467A1 (en) | 2003-03-11 | 2003-04-25 | Process for the preparing of hardcapsule formulation containing lansoprazole |
PCT/KR2003/000835 WO2004080440A1 (en) | 2003-03-11 | 2003-04-25 | Process for the preparing of hardcapsule formulation containing lansoprazole |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0015149A KR100535228B1 (ko) | 2003-03-11 | 2003-03-11 | 란소프라졸함유 경질캅셀제의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040080250A KR20040080250A (ko) | 2004-09-18 |
KR100535228B1 true KR100535228B1 (ko) | 2005-12-08 |
Family
ID=37364991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0015149A KR100535228B1 (ko) | 2003-03-11 | 2003-03-11 | 란소프라졸함유 경질캅셀제의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100535228B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2944971B1 (fr) * | 2009-04-30 | 2012-09-07 | Roquette Freres | Coagglomerats de mannitol et d'amidon granulaire comprimables et a ecoulement libre |
-
2003
- 2003-03-11 KR KR10-2003-0015149A patent/KR100535228B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR20040080250A (ko) | 2004-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6491950B1 (en) | Controlled release pharmaceutical composition | |
KR100459363B1 (ko) | 양성자펌프억제제를함유하는다단위발포성제형 | |
KR101157220B1 (ko) | 리팍시민을 포함하는 위내성 약학적 제제 | |
CN101636152B (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
JP4789806B2 (ja) | パントプラゾール多粒子処方 | |
CN103458880A (zh) | 口服给药的单位剂型 | |
CA2637444C (en) | Coated pharmaceutical composition of tolterodine or a salt thereof having rapid dissolution at acidic conditions and slow dissolution at higher ph values | |
BRPI0716436B1 (pt) | sistema de liberação controlada e método para fabricação do mesmo | |
EP0551820A1 (de) | Geschmacksmaskierte pharmazeutische Mittel | |
WO2010122583A2 (en) | Oral pharmaceutical compositions of acid labile substances | |
CN101087588B (zh) | 包被的药物递送制剂 | |
KR20030059314A (ko) | 산 불안정성 활성 성분을 포함하는 페이스트 형태의 약학제제 | |
KR101122447B1 (ko) | 신규 제제 | |
WO2006049564A1 (en) | New modified release pellet formulations for proton pump inhibitors | |
WO2005077342A1 (en) | Enterically coated lansoprazole microtablets | |
US20090324728A1 (en) | Pharmaceutical compositions comprising amorphous benzimidazole compounds | |
BRPI0615014A2 (pt) | composição farmacêutica sólida compreendendo 1-(4-cloroanilino)-4-(4-piridilmetil)ftalazina e um modificador de ph e uso da mesma | |
KR20180042853A (ko) | 액체 복용 형태로의 다층 약제학적 활성 화합물-방출 미세입자 | |
JP5009482B2 (ja) | 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤 | |
CA2434641A1 (en) | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability | |
US20110311625A1 (en) | Solid dosage forms of fenofibrate | |
BR112013003158B1 (pt) | composições farmacêuticas de antagonistas do receptor glutamato metabotrópico 5 (mglu5) | |
WO2004080440A1 (en) | Process for the preparing of hardcapsule formulation containing lansoprazole | |
KR100535228B1 (ko) | 란소프라졸함유 경질캅셀제의 제조방법 | |
CA2520813C (en) | Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121017 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131120 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141201 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20151102 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161124 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171123 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190917 Year of fee payment: 15 |